AVEO PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 115
- Market Cap
- -
- Website
- http://www.aveooncology.com
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Conditions
- Metastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 410
- Registration Number
- NCT06064877
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California Los Angeles, Westwood, California, United States
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05865535
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT04987203
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center - Monmouth - Oncology, Middletown, New Jersey, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Chao Family Comprehensive Cancer Center, UC Irvine, Irvine, California, United States
A Phase 1 Study of AV-380 in Healthy Subjects
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04815551
- Locations
- 🇺🇸
Biotrial Inc., Newark, New Jersey, United States
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: Ficlatuzumab
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Registration Number
- NCT04100330
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03970616
- Locations
- 🇺🇸
University of California - Irvine, Orange, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03136627
- Locations
- 🇫🇷
Bordeaux Hospital University Center (CHU), Bordeaux, France
🇫🇷Center Léon Bérard, Lyon, France
🇫🇷Centre Paul Strauss, Strasbourg, France
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT02627963
- Locations
- 🇨🇦
Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada
🇺🇸New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02318368
- Locations
- 🇦🇺
Frankston Hospital, Frankston, Victoria, Australia
🇮🇹IRCCS Ospedale S.Raffaele, Milano, Italy
🇮🇹IRCCS Istituto Clinico Humanitas, Rozzano MI, Italy
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
- Conditions
- Mullerian Mixed Tumor of Ovary
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Registration Number
- NCT02090127
- Locations
- 🇺🇸
START, San Antonio, Texas, United States